Lin Ning

Lin Ning is a seasoned professional in the life sciences and biotechnology sectors, currently serving as a Senior Associate at Dolby Family Ventures, where focus is on investments in neurodegeneration, psychiatric disorders, and neuromodulation. As the Founder and principal consultant of Vysta Bio, Lin provides advisory services to investors and startups in the biotech market. Lin also contributes to the field as a writer for An Ounce of Biotechnology, sharing insights on trends and innovations. Previously held roles include Venture Partner at Valkyrie Fund I LP, Lead Analyst at Mythos Biotechnology Fund, and Postdoctoral Fellow at Stanford University, where significant work involved drug discovery tools and kinase inhibitors. Academic credentials include a Ph.D. in Neuroscience/Biochemistry and a postdoctoral fellowship at Stanford University, with a supplementary degree from Stanford Graduate School of Business.